Pfizer, Moderna COVID-19 Boosters Effectiveness Wanes After Four Months: CDC Study

COVID-19 vaccine boosters from Pfizer Inc PFEBioNTech SE BNTX and Moderna Inc MRNA become less effective after four months but still provide significant protection against hospitalization, a CDC study found.

  • While vaccine efficacy was still strong two months after a booster shot, it declined significantly after four months.
  • Efficacy against COVID-19–associated emergency department visits and hospitalization was 87% and 91%, respectively, during the two months after a third dose and decreased to 66% and 78% by the fourth month after a third dose. 
  • Related: Menstrual Irregularities Cases After mRNA COVID-19 Vaccine - EMA Reviews Cases.
  • Protection against hospitalizations exceeded that against emergency department visits.
  • Researchers said the results suggest that additional boosters may be needed.
  • "The finding that protection conferred by mRNA vaccines waned in the months after receipt of a third vaccine dose reinforces the importance of further consideration of additional doses to sustain or improve protection against COVID-19–associated ED/UC encounters and COVID-19 hospitalizations," CDC wrote.
  • Price Action: MRNA shares are down 12.1% at $141.84, PFE stock is down 2.86% at $49.33, and BNTX shares are down 8.59% at $156.27 during the market session on the last check Monday.
Loading...
Loading...
BNTX Logo
BNTXBioNTech SE
$105.280.84%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
64.14
Growth
Not Available
Quality
Not Available
Value
56.68
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...